Probenecid
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Probenecid: From Uricosuric Therapy (Gout) to Renal Hypouricemia
One-Sentence Summary
Probenecid is a classic uricosuric agent, traditionally used to lower serum urate in gout/hyperuricemia by blocking renal urate reabsorption (URAT1). The TxGNN model predicts a possible link to Renal Hypouricemia (score 99.73%), but the supporting literature — 0 clinical trials and 20 publications, mostly describing probenecid used as a diagnostic challenge test rather than a treatment — points to an opposite-direction, likely spurious pharmacological signal. This candidate, and all 9 other candidates predicted for probenecid in this evidence pack, are flagged Hold.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not supplied in this evidence pack (TFDA/TGA label data is a blocking data gap). Probenecid is generically known as a uricosuric agent for gout/hyperuricemia — general pharmacology knowledge, not a sourced regulatory indication |
| Predicted New Indication | Renal Hypouricemia (hypouricemia, renal) |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L4 |
| Australia Market Status | Not marketed in Australia |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for probenecid is not available in this evidence pack (data gap). Based on general pharmacology knowledge, probenecid inhibits URAT1-mediated urate reabsorption in the renal proximal tubule, which increases urinary urate excretion and lowers serum urate — the basis for its historic use in gout and hyperuricemia.
Renal hypouricemia is the opposite clinical state: an inherited or acquired defect (typically loss-of-function mutation in SLC22A12/URAT1) that causes excessive urate loss and abnormally low serum urate. Pharmacologically, probenecid would be expected to worsen, not treat, this condition — it is one of the agents historically used as a diagnostic urate-clearance challenge test in patients already suspected of having the disorder.
Reviewing the underlying literature confirms this: almost all cited papers are case reports or genetic/molecular studies describing renal hypouricemia as a disease entity, with probenecid appearing only as a diagnostic probe (alongside pyrazinamide) to characterise a patient’s urate transport defect — not as a therapeutic intervention. This pattern is consistent with TxGNN generating the association through shared URAT1/urate-pathway biology in the knowledge graph, without capturing the direction of the pharmacological effect. The same caution applies to the other 9 ranked candidates for probenecid in this pack (Lesch-Nyhan syndrome, HGPRT deficiency, cholelithiasis, and a cluster of hepatobiliary conditions sharing an identical score of 96.59%, plus “disorder of phenylalanine metabolism,” where the cited literature actually concerns the unrelated “probenecid test” for CSF dopamine turnover in Parkinson’s disease research) — all are scored Hold, and several are explicitly noted as likely non-specific clustering or diagnostic-test confusion rather than genuine treatment signals.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 14694169 | 2004 | Cohort (molecular analysis) | J Am Soc Nephrol | Genetic study of 32 renal hypouricemia patients establishing SLC22A12/URAT1 loss-of-function as the cause — describes disease mechanism, not probenecid treatment |
| 31650389 | 2020 | Review | Clin Rheumatol | Narrative review of hypouricemia aetiology for rheumatologists; no probenecid treatment data |
| 16678460 | 2006 | Review/Case report | Mol Genet Metab | Overview of hereditary renal hypouricemia caused by SLC22A12 mutations |
| 7771493 | 1995 | Case report/Review | Am J Kidney Dis | Exercise-induced acute renal failure in renal hypouricemia; discusses prevention, not probenecid therapy |
| 3813739 | 1987 | Case report | Arch Intern Med | Diabetic patients with renal hypouricemia; probenecid used diagnostically to characterise the urate clearance defect |
| 14655203 | 2003 | Case report | Am J Kidney Dis | Siblings with hereditary renal hypouricemia and exercise-induced acute renal failure |
| 1944743 | 1991 | Case report | Nephron | Type 1 diabetics with renal hypouricemia; uricosuric mechanism study |
| 1656732 | 1991 | Case report | Am J Kidney Dis | Cholangiocarcinoma-associated severe renal hypouricemia; probenecid/pyrazinamide used as diagnostic probes |
| 8341392 | 1993 | Case report | Nephron | Novel renal hypouricemia subtype unresponsive to probenecid/pyrazinamide challenge |
| 7099326 | 1982 | Case report | Nephron | Familial renal hypouricemia; urate excretion paradoxically decreased by probenecid (diagnostic test) |
Note: none of the above papers evaluate probenecid as a therapy for renal hypouricemia — it is used only as a diagnostic urate-clearance challenge agent.
Australia Market Information
Probenecid is not currently registered on the ARTG (0 entries) and is not marketed in Australia.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information. Detailed warnings, contraindications, and drug interaction data are not available in this evidence pack (blocking data gap — TFDA label not yet sourced).
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic direction is inverted — probenecid pharmacologically induces/worsens hypouricemia rather than treating it, and the cited literature describes probenecid only as a diagnostic challenge test in renal hypouricemia patients, not as a therapeutic agent. All 10 TxGNN-predicted indications for probenecid in this pack (including Lesch-Nyhan syndrome, HGPRT deficiency, and a cluster of hepatobiliary conditions sharing an identical score) carry the same Hold recommendation, several flagged as likely non-specific knowledge-graph clustering rather than genuine repurposing signals.
To proceed, the following is needed:
- TFDA/TGA-approved Product Information (warnings, contraindications, DDI) — currently a blocking gap
- Confirmed original indication and mechanism-of-action data for probenecid
- Independent pharmacological review of why TxGNN generated this and the other 9 candidate associations, before considering any further evaluation stage
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.